Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Completed · Phase 3

Conditions studied: Dry Eye Disease

In brief

This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit) for an individual duration of participation of approximately 15 weeks.

Key facts

Study ID
NCT05360966
Run by
Aerie Pharmaceuticals
People needed
467
Starts
2022-07-18
Expected to finish
2023-10-17
Last updated by the study team
2025-07-23

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.